Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting that the closer to the conference call the more hysteria there is.
With those dead cat bounces going ever higher, pretty soon that dead cat will reach the moon.
None of those drugs has ever been tested in combination with leronlimab. If you look at that list they threw every monoclonal antibody and immunomodulator at it, which is complete nonsense.
I pulled one out of the mix at random (Codrituzumab) just to see. Codrituzumab is an Anti-glypican-3 monoclonal antibody. Inhibiting glypican-3 increases caspase-3 which results in tumor cell death. Leronlimab blocking CCR5 also increases caspase-3 leading to tumor cell death. No negative drug interaction and most likely no added benefit.
No offense taken. You aren't going to know what my knowledge level is and a year ago I knew very little. It's always best to question because there's a lot of BS flying around.
Conrad says "Those shares ain't going to move themselves."
You don't think I know what I'm talking about, no problem. You need outside confirmation, here you go.
The under cover footage seems to be of stock footage and clips. What's undercover about that? 51 cards short of a deck.
I saw on Dr. Dalton's twitter he won the IFAH Top 100 Healthcare Leaders Award. He seems in good company.
Vasayo Accoladed The “Top 50 Companies in Health Care” Award at IFAH, Vegas 2019
https://floridajustice.com/vasayo-new-magic-pill-mlm/
The side effects of the common cold are caused by inflammation. Leronlimab boosts the immune system by downregulating inflammatory M1 macrophages and preferentially upgrading M2 macrophages (CD8+ T-cells) and natural killer T-cells. The exact same MOA as for COVID-19.
However it's not a really cost effective way to treat a cold.
It's 3:20 Pm Eastern Standard Time.
IL-6 inhibitors that do a half-assed job, lower immune response to make fighting the virus harder and have bad side effects are hardly amazing.
The loosening of restrictions means it will still be around though at a lesser level.
Doctors will perform interventions in the placebo group if necessary which is why leronlimab will be approved on secondary endpoints. Of course the best intervention is leronlimab and I'm sure the results of those who have had intervention will be written up in a supplement to the FDA submission.
Gilead has no SEC financial filings listed before 1996 Even though it's IPO was 1992. So what were they hiding?
I would expect IV to ramp up the same bioavailability within 24 hours that it takes 3 days for via subcutaneous injection.
I'm surprised it's that high. He must have averaged up some. I started buying a bit earlier so I averaged down to .40.
Being large molecule leronlimab has almost no bioavailability if taken orally. That why it's either administered IV or subcutaneous.
Sounds like Gilead circa 1989.
Not much of a dump if it's going up.
You trust analysts? You must be new to investing. They obviously haven't considered a product that actually works coming along and taking away that market share. But it's sure nice to know how much the drug that's going to do it is worth.
Only a JAK inhibitor, guess what drug does that and oh so much more. Here's a hint, it's not owned by Gilead. Once again Gilead will suffer.
CYDY is on the OTCQB market which has higher standards than the pink sheet market. Audited annual financials and we follow the SEC Reporting Standard.